196 related articles for article (PubMed ID: 21632856)
1. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
Zecevic A; Sampath D; Ewald B; Chen R; Wierda W; Plunkett W
Clin Cancer Res; 2011 Jul; 17(14):4731-41. PubMed ID: 21632856
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.
Moufarij MA; Sampath D; Keating MJ; Plunkett W
Blood; 2006 Dec; 108(13):4187-93. PubMed ID: 16954499
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Pepper C; Lowe H; Fegan C; Thurieau C; Thurston DE; Hartley JA; Delavault P
Br J Cancer; 2007 Jul; 97(2):253-9. PubMed ID: 17579621
[TBL] [Abstract][Full Text] [Related]
4. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
[TBL] [Abstract][Full Text] [Related]
5. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
[TBL] [Abstract][Full Text] [Related]
6. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway.
Zhou Z; Fang Q; Li P; Ma D; Zhe N; Ren M; Chen B; He Z; Wang J; Zhong Q; Wang J
Life Sci; 2019 Sep; 232():116583. PubMed ID: 31226417
[TBL] [Abstract][Full Text] [Related]
7. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.
Yamauchi T; Nowak BJ; Keating MJ; Plunkett W
Clin Cancer Res; 2001 Nov; 7(11):3580-9. PubMed ID: 11705880
[TBL] [Abstract][Full Text] [Related]
8. Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia.
Lohmann G; Vasyutina E; Bloehdorn J; Reinart N; Schneider JI; Babu V; Knittel G; Crispatzu G; Mayer P; Prinz C; Muenzner JK; Biersack B; Efremov DG; Chessa L; Herling CD; Stilgenbauer S; Hallek M; Schobert R; Reinhardt HC; Schumacher B; Herling M
Leukemia; 2017 May; 31(5):1177-1186. PubMed ID: 27773933
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
Rebolleda N; Losada-Fernandez I; Perez-Chacon G; Castejon R; Rosado S; Morado M; Vallejo-Cremades MT; Martinez A; Vargas-Nuñez JA; Perez-Aciego P
PLoS One; 2016; 11(4):e0154159. PubMed ID: 27101369
[TBL] [Abstract][Full Text] [Related]
10. Targeting base excision repair suggests a new therapeutic strategy of fludarabine for the treatment of chronic lymphocytic leukemia.
Bulgar AD; Snell M; Donze JR; Kirkland EB; Li L; Yang S; Xu Y; Gerson SL; Liu L
Leukemia; 2010 Oct; 24(10):1795-9. PubMed ID: 20811400
[No Abstract] [Full Text] [Related]
11. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine.
Huang P; Sandoval A; Van Den Neste E; Keating MJ; Plunkett W
Leukemia; 2000 Aug; 14(8):1405-13. PubMed ID: 10942236
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Li L; Keating MJ; Plunkett W; Yang LY
Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
[TBL] [Abstract][Full Text] [Related]
13. Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.
Starczewska E; Beyaert M; Michaux L; Vekemans MC; Saussoy P; Bol V; Arana Echarri A; Smal C; Van Den Neste E; Bontemps F
Oncotarget; 2016 Jun; 7(25):38367-38379. PubMed ID: 27223263
[TBL] [Abstract][Full Text] [Related]
14. ZGDHu-1 and fludarabine have a synergistic effect on apoptosis of chronic lymphocytic leukemia cells.
Qiu L; Liu J; Wang Z; Hu W; Huang Q; Zhou Y
Oncol Rep; 2015 Sep; 34(3):1239-48. PubMed ID: 26165829
[TBL] [Abstract][Full Text] [Related]
15. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
Lozano-Santos C; Amigo-Jiménez I; Nova-Gurumeta S; Pérez-Sanz N; García-Pardo A; García-Marco JA
Biochem Biophys Res Commun; 2015 May; 461(2):243-8. PubMed ID: 25869069
[TBL] [Abstract][Full Text] [Related]
17. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.
Walsby E; Pearce L; Burnett AK; Fegan C; Pepper C
Oncotarget; 2012 May; 3(5):525-34. PubMed ID: 22619113
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.
Balin-Gauthier D; Delord JP; Pillaire MJ; Rochaix P; Hoffman JS; Bugat R; Cazaux C; Canal P; Allal BC
Br J Cancer; 2008 Jan; 98(1):120-8. PubMed ID: 18182978
[TBL] [Abstract][Full Text] [Related]
19. DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Horie R; Watanabe M; Okamura T; Taira M; Shoda M; Motoji T; Utsunomiya A; Watanabe T; Higashihara M; Umezawa K
Leukemia; 2006 May; 20(5):800-6. PubMed ID: 16525497
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
Keating MJ; McLaughlin P; Plunkett W; Robertson LE; O'Brien S; Gandhi V; Gregoire V; Yang L; Cabanillas F
Ann Oncol; 1994; 5 Suppl 2():79-83. PubMed ID: 8204523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]